Abstract
ABSTRACT Background QoL and preference/utility data have not been extensively collected in post-docetaxel (D) mCRPC. Canada collected EQ-5D-3L data in this setting as part of the single-arm multicenter EAP for Cabazitaxel. Methods Between May 2011 and February 2012, 61 evaluable patients (pts) were enrolled at 9 centers. EQ–5D-3L data was collected and analyzed at baseline and after every cycle. EQ-5D health state index (HIS) and visual analog scale (VAS) data were collected. HIS data were converted into utility values using the UK tariff from Dolan 1997. The relationship between baseline ECOG performance status (PS) and EQ-5D values (HIS and VAS) across visits was examined. Results At time of abstract submission, baseline characteristics and EQ-5D data were available for 58 pts: median age 65 years, 94% of pts ECOG PS 0 or 1, 85% had bone metastases, and 45% received at least 6 cycles of cabazitaxel. Significant improvements (p Conclusions Improvements were seen on the EQ-5D in the Pain domain, with more than a third of pts reaching a MID on the EQ-5D by cycle 6. Improvements in pain, a common symptom in mCRPC, directly impact pts' experience of their disease. The poster will present updated data. Disclosure F. Saad: Dr Fred Saad sits on the advisory board for Sanofi Canada and has received consultant's honoraria from Sanofi Canada. He is involved in research projects with Sanofi Canada. E. Winquist: Dr Eric Winquist has received travel funding and consultant's honoraria from Sanofi Canada. He is involved in research projects with Sanofi Canada, M. Girard: Employee with Sanofi Canada, S.S. Sridhar: Dr S.S. Sridhar sits on Advisory Boards and receives Research Funding from Sanofi Canada.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call